2015 ANNUAL REVIEW

Innovative Precision Medicine Trial, Lung-MAP,Expands Across NationâMore than 700 sites activatedâ210 patients enrolled May 19, 2015 – Friends Creates Momentum for

Enhancing Patient Input and Regulatory InnovationLeaders from advocacy, industry, science, academiaand government discuss pressing issues with FDAleadership and develop framework for patient input

June 10, 2015 – Friends Convenes Multi-stakeholderForum Exploring Rate-limiting Steps in ManufacturingReadiness for Breakthrough Drug Development

September 9, 2015 – Friends Charts Blueprint forPersonalized MedicineFriends partners with Alexandria Real Estate Equities tohost forum addressing how genetic databases alterresearch

Friends Plays Key Role in House 21st Century Cures Act

âFebruary 23, 2015 – Friends holds congressionalbriefing on 21st Century Cures Act

âMay 21, 2015 – House Energy & CommerceCommittee unanimously passes bill

âJuly 10, 2015 – Bill passes House

JANUARY

FEBRUARY

MAY

JUNE

SEPTEMBER

Breakthrough Continues to Revolutionize DrugDevelopmentFriends was pivotal in creating the designation, movingit from an idea to reality in just 13 months. Since theprogram began there have been:â384 breakthrough therapy designation requestsâ118 designations grantedâ39 FDA approvalsâ30 approvals for novel indications

Within the last year there were:â34 cancer drugs that received the designationâ21 breakthrough cancer drugs approved

October 22, 2015 – Friends Celebrates IncredibleLeaders, AccomplishmentsFriends honors Marlene Malek, Rep. Diana DeGette(D-CO) and Rep. Fred Upton (R-MI) at 19th AnnualCancer Leadership Awards Reception; NIH Dir.Francis Collins surprises attendees through song “If Not Now, Tell Me When”

November 12, 2015 – Friends Partners with PrevisionPolicy to Launch Biopharma CongressKeynotes delivered by CMS Acting Administrator AndySlavitt and FDA CDER Dir. Janet Woodcock; Former FDACommissioners Margaret Hamburg and Mark McClellandiscuss future of FDA with Ellen Sigal

November 17, 2015 – 8th Friends-Brookings AnnualMeetingCaliff makes first appearance post-Senate confirmationhearing; meeting sought recommendations to:âIntegrate new measures of tumor response into drug

development programsâDevelop a framework to improve use of expansion

cohorts to support drug approvalsâFacilitate incorporation of patient reported outcomes

into drug development and support improvedcollaboration between government and sponsorsOCTOBER

NOVEMBER

DECEMBER

Breakthrough Designations by

Therapeutic Categories

Other20.8%

Rare InheritedDisorders

13.2%

Cancer49.1%

InfectiousDisease14.2%

Cardiovascular2.8%

About Friends Friends Board of Directors

BOARD OF DIRECTORS

Pennie Abramson, Ph.D. (h.c.)President’s Circle, TheWeizmann Institute of Science

Carolyn “Bo” AldigePresident & Founder, PreventCancer Foundation

Anna Barker, Ph.D. Professor & Director,Transformative HealthcareNetworks, Arizona StateUniversity

Christopher W. HansenPresident, American CancerSociety Cancer Action Network

Sherry Lansing Chief Executive Officer, TheSherry Lansing Foundation

Catherine Ann Stevens, J.D.Partner, Mayer Brown LLP

Mary WoolleyPresident, Research!America

Robert C. Young, M.D.President, RCYMedicine

ExECuTIvE COMMITTEE

Ellen v. Sigal, Ph.D.Chair & Founder, Friends ofCancer Research

Marlene Malek, R.N.President, Friends of CancerResearch

Barbara Duffy Stewart, M.P.H.Executive Director, Association of American Cancer Institutes

Sudip S. Parikh, Ph.D.Vice President & GeneralManager, Health & Analytics,Battelle Memorial Institute

Margaret Foti, Ph.D., M.D. (h.c.)Chief Executive Officer, AmericanAssociation for Cancer Research

Jonathan LeffPartner, Deerfield Management

Joel S. MarcusChairman, Chief Executive, andFounder, Alexandria Real EstateEquities, Inc., Alexandria VentureInvestments

David MitchellPartner, GMMB

Richard Schilsky, M.D.Chief Medical Officer, AmericanSociety of Clinical Oncology

Jeff Allen, Ph.D., Executive Director

Ryan Hohman, J.D., Managing Director, Policy and Public Affairs

Heather Chaney, Managing Director, Program Administration

Berrett Stradford, Director, External Affairs

Samantha Roberts, Ph.D., Director, Scientific Affairs

Marina Kozak, Ph.D., Science Policy Analyst

Mark Stewart, Ph.D., Science Policy Analyst

Michael Shea, Policy Research Associate

Joe Patterson, Public Affairs Associate

Alexi Turbow, Public Affairs Associate

Linda Ostermann, Administrative Coordinator

Thank you to all of the Friends staff and collaborators whocontribute to our work.

A special thanks to:

Friends of Cancer Research (Friends) drivescollaboration among partners from everyhealthcare sector to power advances in science,policy and regulation that speed life-savingtreatments to patients.

During the past 20 years, Friends has beeninstrumental in the creation and implementationof policies ensuring patients receive the besttreatments in the fastest and safest way possible.We’ve been successful to date due to our abilityto convene the right people at the right time andput forth revolutionary, yet realistic ideas.

As we embark on this milestone year, we lookforward to continuing this critical work with ourtrusted partners and continue to lead the way inevolving cancer research and treatment.

2015 Publications

The articles below were created either entirely byor with input from Friends of Cancer Researchand published in 2015.

âThe role of nonrandomized trials in the evaluationof oncology drugs. Clinical Pharmacology andTherapeutics, May 2015.

âImproving evidence developed from population-level experience with targeted agents. ClinicalPharmacology and Therapeutics, May 2015.

âModernizing Measurement of Tumor Response toTherapy: Application to Immunotherapeutics.2015 Conference on Clinical Cancer Research.

âCapturing Symptomatic Adverse Events From thePatients’ Perspective: The Potential Role of theNational Cancer Institute’s PRO-CTCAEMeasurement System. 2015 Conference onClinical Cancer Research.

âThe Blurring of Phase 1, 2 and 3 Trials inOncology: Expansion Cohorts in Phase 1 Trials.2015 Conference on Clinical Cancer Research.

âExamining Manufacturing Readiness forBreakthrough Drug Development. AmericanAssociation of Pharmaceutical Scientists.PharmSciTech, November 2015.

âEnhancing Use of Patient-Centered Data inRegulatory Decision-Making. Friends of CancerResearch and Burroughs Wellcome Fund. 2015.

âRegulatory decision-making meets the real world.Science Translational Medicine, November 2015.

Supporters

INNOvATORS

Alexandria Real Estate Equities Inc /Alexandria Venture Investments

Amgen

AstraZeneca

Bayer HealthCare

Bristol-Myers Squibb Company

Celgene Corporation

Eli Lilly and Company

Genentech

Janssen Pharmaceuticals, Inc.

Marlene and Fred Malek

Merck & Co., Inc.

Novartis PharmaceuticalsCorporation

Pfizer Inc

PhRMA

Ellen and Gerry Sigal

Takeda Oncology

CHAMPIONS

Abbvie

The Abramson Family Foundation

American Association for CancerResearch

American Cancer Society

American Society of Clinical Oncology

Boehringer Ingelheim Pharmaceuticals

EMD Serono

Foundation for the National Institutesof Health

Foundation Medicine Inc.

Gilead

Ken and Virginia Grunley

Helsinn Therapeutics

Illumina

Johnson & Johnson

The Kovler Foundation – Peter andJudy Kovler

Onyx Pharmaceuticals Inc.

Pharmacyclics Inc.

Resnick Family Foundation, Inc.

PARTNERS

The Rona and Jeffrey AbramsonFoundation

ADP Foundation, Inc.

Association of American CancerInstitutes

Battelle

Burroughs Wellcome Fund

Greenleaf Health LLC

Interstate Hotels and Resorts

Lionsgate

The Meltzer Group

Miller & Long Company, Inc.

National Patient AdvocateFoundation

Prevision Policy

The Abe & Kathryn SelskyFoundation Inc.

Klara and Larry Silverstein

Vertex Pharmaceuticals

A note from the Executive Director

On behalf of Friends of Cancer Research, I would like to thank all of our supporters andcollaborators for your steadfast commitment to our mission. We’ve made great strides in developingnew models to enhance science and innovation.

As we embark on our 20th year, we look forward to continuing partnerships built on cutting-edgescience to create solutions that will change the cancer landscape.

Your support is vital to ensuring this work can continue.

With great appreciation,

Jeff Allen, Ph.D., Executive Director, Friends of Cancer Research

Miriam and Sandford AinJeff Allen and Kevin KenneyAnna BarkerGrace BenderThe Honorable and Mrs. Stuart BernsteinHarold BeznosBiotechnology Industry OrganizationKatherine and David BradleyHenry and Rachel BremC.R. Bard, Inc.Marcia CarlucciCBS CorporationCDWThe Honorable William and Mrs. Janet

CohenDana-Farber Cancer InstituteDeerfieldDick and Betsy DeVosMr. and Mrs. Richard DubinEdelmanAlvin and Joan EinbenderEplus, Inc.Diana and Michael David EpsteinSuellen EstrinLucy Fisher and Doug WickRobert and Shari Friedman

Suzy and Bob PencePeregrine Pharmaceuticals, Inc.Edwin and Linda PhelpsLeland and Mary PillsburyResearch!AmericaCatherine B. Reynolds FoundationMace and Joyce RothenbergVicki and Roger SantSidney Kimmel Comprehensive Cancer Center

at Johns Hopkins UniversityAnnie Simonian TotahMr. and Mrs. Albert H. SmallRobert H. Smith Family FoundationPaul G. SternCatherine StevensMichael and Leslie TiveUniversity of Kansas Cancer CenterUniversity of Maryland Greenbaum Cancer

CenterUniversity of Pittsburgh Cancer InstituteUniversity of Texas MD Anderson Cancer CenterGeorge Vande WoudeAndy and Madelyn von EschenbachVornado - Charles E. SmithSharon WeissLynne Zydowsky / Zydowsky Consultants

Norma Lee and Morton Funger - TheFunger Foundation Inc.

General DynamicsThe George Washington UniversityThe Honorable Joseph and Mrs. Alma

GildenhornJan and Ronald GreenbergHerbert Family FoundationRyan Hohman & Bradford RathgeberKids v CancerAnnette KirshnerKlein Financial CorporationSherry LansingLeukemia & Lymphoma SocietyLockton Companies, Inc.Fred and Britlan MalekJoel and Deborah MeiselAlan and Amy MeltzerMilken Family FoundationMK & AMoffitt Cancer Center & Research InstituteBarbara MoserNational Pharmaceutical CouncilMichelle and Chris OlsonOSU - The James Cancer HospitalOtsuka America Pharmaceutical, Inc.

ADvOCATES

Supporters

John AdelmanSusan AllenShalom BaranesSteven and Shari BloomAbigail BluntSusan and Dixon ButlerBridget CaraccioloCEO Roundtable on CancerHeather ChaneyDr. Tony and Robyn ColesRoger Cossack and Jane

HannawaySevasti DamesSusan DavisAnn DaytonAnita DaytonChip DigginsRichard and Judy DolingSamia FaroukiFasterCures

Joel and Barbara FinkelsteinStuart GellerGretchen GorogIra and Judith GottfriedAnne GradyLeonard GreenbergGerard and Pamela HeiberT. Patrick and Ann Marie HillWilhemina HolladayJacinta HurleyGail and Benjamin JacobsDianne KayFrank and Cathy KeatingDebra KirshnerMarina KozakBrendan and Leanna LalorClimis and Carol LascarisPaul LewisTom and Bonnie MillerDavid and Nicole Mitchell

PATRONS

Amy MuhlbergMary Ann and Scott

NordheimerMelanie and Larry NussdorfLinda OstermannJoe PattersonGeraldine PilzerPauline RandallRenay RegardieWilliam Regardie Living TrustSamantha RobertsMark and Elizabeth RogersEric and Kimberly RubinGenny and Fred RyanMatthew and Lynne ShankMargaret ShannonMary SingerBerrett StradfordCourtney StrausCarl Striler

Alexi TurbowUniversity of Miami Sylvester

Comprehensive Cancer CenterDaniel and Ann Von HoffGeoff WahlMarilyn and Hal WeinerRobert & Terri WeissAmbassador C. Howard WilkinsMyles Wittenstein Li YanRobert C. YoungNancy Zirkin

In-KindAlston + BirdDeerfield InstituteGCS, Inc.SIGAL ConstructionThe West Foundation